Skip to main content

Table 3 Univariate-Cox-regression-analysis of known prognostic factors CTAs and NY-BR-1 of breast-cancer patients

From: Cancer testis antigens and NY-BR-1 expression in primary breast cancer: prognostic and therapeutic implications

   DFS    OS  
  HR 95% CI p HR 95% CI P
Age vs median 0,884 0,530–1,475 0,637 0,987 0,542–1,796 0,966
Tumor grade 1,521 0,930–2,488 0,095 1,652 0,903–3,022 0,104
Tumor stage 1,808 1,241–2,632 0,002 1,988 1,292–3,058 0,002
Lymph node status 2,971 1,730–5,104 0 3,348 1,714–6,537 0
Histological type 0,864 0,672–1,111 0,255 0,855 0,624–1,170 0,327
ER/PR status 0,526 0,307–0,901 0,019 0,775 0,399–1,505 0,451
HER2/neu status 1,064 0,826–1,369 0,632 0,986 0,727–1,337 0,929
MAGE A1 MA454 1,278 0,564–2,898 0,557 2,284 0,910–5,732 0,078
M3H67 reactivity 2,85 1,350–6,017 0,006 4,27 1,834–9,941 0,001
57B reactivity 3,406 1,15–10,03 0,026 3,446 1,00–11,77 0,049
NY-ESO-1 E978 1,272 0,563–2,877 0,563 0,805 0,242–2,684 0,724
GAGE #26 1,988 0,875–4,516 0,101 1,98 0,739–5,303 0,174
MAGE A 6C1 1,65 0,498–5,466 0,413 1,876 0,435–8,087 0,399
NY-BR-1 #5 1,522 0,816–2,839 0,186 1,235 0,554–2,752 0,606
  1. Abbreviations: DFS Disease free survival; OS Overall survival; HR Hazard ratio; CI Confidence interval.